CSF treatment improved the hepatic steatosis, intralobular inflammation, and balloon-like changes while decreasing the lipid deposition in HFD rats by decreasing the levels of TG, AST, and ALT and down-regulating the expression of TLR4, MyD88, NF-κB, TNF-α, IL-6, as well as IL-8 [73]. This evidence concerns the gene NFKB1 and fatty liver disease.